Scholarlink

Background <p>TIA-1 (T-cell intracellular antigen 1) is an RNA-binding protein central to the formation of stress granules (SGs) and modulation of inflammatory responses. Recent research has identified TIA-1 as a key player in neurodegenerative diseases, especially those involving Tau pathology such as in Alzheimer’s disease (AD), in a subtype-dependent manner. Disease-modifying therapies for AD and related dementias are emerging, but their effectiveness hinges on timely and accurate diagnosis. This underscores urgent need for easily accessible and reliable blood biomarkers for early detection, disease monitoring, and subtype differentiation.</p> Methods <p>Accordingly, in this pilot study, we evaluated the plasma TIA-1 levels in healthy controls and across spectrum of neurodegenerative diseases to assess its clinical and biological significance. Plasma TIA-1 concentrations were measured in Alzheimer’s disease, mild cognitive impairment due to AD (MCI-AD), vascular cognitive impairment (VCI), and other neurodegenerative diseases (NDs: synucleinopathies and tauopathies), and compared to healthy controls. Receiver operating characteristic (ROC) analyses and correlation studies with established biomarkers and cognitive scores were performed.</p> Results <p>Plasma TIA-1 levels were significantly reduced in AD, MCI-AD, VCI, and non-AD neurodegenerative diseases (synucleinopathies and tauopathies) compared to healthy controls, with the greatest reductions observed in non-AD neurodegenerative diseases. Strikingly, combined measurement of plasma TIA-1 and glial fibrillary acidic protein (GFAP) improved differentiation of AD subtypes, particularly distinguishing rpAD from non-rpAD cases. Plasma TIA-1 levels correlated with key biomarkers of neurodegeneration (p-Tau, Aβ42, NFL) and cognitive decline, especially in early AD (MCI-AD). Notably, plasma TIA-1 mirrored the discriminatory patterns of CSF t-Tau and p-Tau, distinguishing non-AD neurodegenerative diseases from specifically rpAD subtype, indicating that plasma TIA-1 captures the same underlying pathophysiological processes as the “gold standard” CSF markers.</p> Conclusions <p>Plasma TIA-1 is a promising biomarker candidate for neurodegenerative diseases, with alterations that reflect disease presence and severity. In this pilot cohort, its combination with GFAP noticeably improved discrimination between AD subtypes, supporting its potential added value in composite biomarker approaches. Given its accessibility, TIA-1 is a strong candidate for further evaluation as part of future blood-based biomarker panels, although it’s clinical utility still needs confirmation in larger, independent studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduced plasma TIA-1: bridging established pathology and novel biomarker potential

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Neelam Younas,
  • Abrar Younas,
  • Peter Hermann,
  • Leticia Camila Fernandez Flores,
  • Kathrin Dittmar,
  • Saima Zafar,
  • Holger Budde,
  • Tobias J. Legler,
  • Tayyaba Saleem,
  • Matthias Schmitz,
  • Inga Zerr

摘要

Background

TIA-1 (T-cell intracellular antigen 1) is an RNA-binding protein central to the formation of stress granules (SGs) and modulation of inflammatory responses. Recent research has identified TIA-1 as a key player in neurodegenerative diseases, especially those involving Tau pathology such as in Alzheimer’s disease (AD), in a subtype-dependent manner. Disease-modifying therapies for AD and related dementias are emerging, but their effectiveness hinges on timely and accurate diagnosis. This underscores urgent need for easily accessible and reliable blood biomarkers for early detection, disease monitoring, and subtype differentiation.

Methods

Accordingly, in this pilot study, we evaluated the plasma TIA-1 levels in healthy controls and across spectrum of neurodegenerative diseases to assess its clinical and biological significance. Plasma TIA-1 concentrations were measured in Alzheimer’s disease, mild cognitive impairment due to AD (MCI-AD), vascular cognitive impairment (VCI), and other neurodegenerative diseases (NDs: synucleinopathies and tauopathies), and compared to healthy controls. Receiver operating characteristic (ROC) analyses and correlation studies with established biomarkers and cognitive scores were performed.

Results

Plasma TIA-1 levels were significantly reduced in AD, MCI-AD, VCI, and non-AD neurodegenerative diseases (synucleinopathies and tauopathies) compared to healthy controls, with the greatest reductions observed in non-AD neurodegenerative diseases. Strikingly, combined measurement of plasma TIA-1 and glial fibrillary acidic protein (GFAP) improved differentiation of AD subtypes, particularly distinguishing rpAD from non-rpAD cases. Plasma TIA-1 levels correlated with key biomarkers of neurodegeneration (p-Tau, Aβ42, NFL) and cognitive decline, especially in early AD (MCI-AD). Notably, plasma TIA-1 mirrored the discriminatory patterns of CSF t-Tau and p-Tau, distinguishing non-AD neurodegenerative diseases from specifically rpAD subtype, indicating that plasma TIA-1 captures the same underlying pathophysiological processes as the “gold standard” CSF markers.

Conclusions

Plasma TIA-1 is a promising biomarker candidate for neurodegenerative diseases, with alterations that reflect disease presence and severity. In this pilot cohort, its combination with GFAP noticeably improved discrimination between AD subtypes, supporting its potential added value in composite biomarker approaches. Given its accessibility, TIA-1 is a strong candidate for further evaluation as part of future blood-based biomarker panels, although it’s clinical utility still needs confirmation in larger, independent studies.